Greece: Course of payments from the Organization to the healthcare providers
EOPYY (the Greek National Organization for the Provision of Health Services) proceeds with the plan for the rationalization of payments from the Organization to the health care (HC) providers, in cooperation and with the assistance of the Ministry of Health, states an EOPYY press release.
More specifically, a payment schedule is implemented to pharmaceutical companies and hospitals:
- Already via the special schedule for the settlement of outstanding debts of the General Administration agencies to third parties, the amount of 270 million euros ($306 million) has been disbursed to the Pharmaceutical Companies.
- From September, additional payments by EOPYY will proceed for the settlement of outstanding debts to pharmaceutical companies and to other HC Providers, thus reducing by the respective amounts the debts of the Organization.
- As regards the State hospitals and the Special Regime Hospitals, EOPYY has proceeded or scheduled payments of 166.5 million euros ($188.6 million) in August 2016.
- In parallel, the clearance of filings by the HC Providers of EOPYY continues. More specifically, until August 24, 2016, payment warrants had been issued for filings of expenses for January-February-March for various categories of HC Providers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze